mined at thoracotomy and by pathological staging after surgery also by the TNM system. All available surgical specimens (n = 18) were re-examined by a pathologist (WT). Fourteen patients received postoperative chemotherapy. As the study spanned 13 years, chemotherapy protocols varied. One patient also received thoracic irradiation to the mediastinum. Ten patients received prophylactic cranial irradiation after completion of chemotherapy. At relapse patients were treated with chemotherapy, radiotherapy or both, if appropriate.
Survival was calculated from the date of surgery. Survival curves were constructed according to the product limit Kaplan-Meier method. Deaths within 30 days of operation were included in the estimation of survival data. Pathological re-evaluation of the resected specimens (n = 18) revealed one carcinoid, 15 pure small cell carcinoma of the lung, and two mixed small cell and non-small cell carcinoma of the lung. All patients were offered postoperative chemotherapy. Four patients refused because they considered the operation surgically curative; one refused because of deteriorating performance status. Two patients died before chemotherapy was due to commence. Starting within six weeks of surgery 2-5 courses of a 3-4 drug chemotherapy regimen were administered to 14 patients, including 12 with pure small cell carcinoma of the lung, one with mixed small cell and non-small cell cancer, and one with atypical carcinoid.
Survival at the end of 1991 for the 20 patients with a diagnosis of small cell carcinoma of the lung is shown in the figure. The patient with an atypical carcinoid was excluded. The median survival was 29 months (range two to 133 + months). Median survival for patients with pathological stage I and II disease (n = 13) was 40+ months (range nine to 133 + months) and 20 months (range two to 116+ months) for patients with stage III disease (n=7) (p<0-05). No significant difference was found when survival was analysed for preoperative clinical stage. Median survival for patients with clinical stage I (n = 11) was 33 months (range four to 133+ months) and 29 months (range two to 166 + months) for those with clinical stage II (n = 9). Median survival in patients following pneumonectomy (n= 11) was 25 months (range two to 116+ months), which was similar to those undergoing lobectomy (n = 9), 33 + months (range nine to 133 + months).
Seven patients are alive and disease free at 19 to 116 months after surgery. Another relapsed (or had a second primary) 101 months after resection but is alive on chemotherapy with disease (133 months). One patient died 50 days after surgery at home from an unknown cause and one died with no evidence of disease nine months postoperatively. Ten that in patients with small cell carcinoma of the lung presenting with a solitary pulmonary nodule the final diagnosis was correct in only 60% of cases.
It is tempting to conclude that, for selected patients with small cell carcinoma of the lung, surgery is the best treatment. The five year survival of our 20 patients is 25%. As in other studies there was a significant difference in median survival between patients with pathological stage I and II disease and those with pathological stage III.3613 However, there was no survival difference between those with clinical stage I and II disease, reflecting the limitations of clinical staging.3 14 We conclude that surgery should be considered in patients with favourable preoperative staging. The relapse rate and survival among patients who did or did not receive adjuvant chemotherapy was similar and five of the untreated patients had stage I disease.
